Aprea Therapeutics, Inc. (APRE) vs GT Biopharma, Inc. (GTBP)
A side-by-side comparison of Aprea Therapeutics, Inc. and GT Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APRE
Aprea Therapeutics, Inc.
$0.68HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
GTBP
GT Biopharma, Inc.
$6.16HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — APRE vs GTBP
growth of $100 · dividends reinvested · last 7yAPRE -99.8% (-60.0%/yr)GTBP -99.7% (-55.5%/yr)GTBP compounded faster over this window
APRE GTBP
APRE vs GTBP: by the numbers
- •APRE is the larger company ($8M vs $8M market cap).
Metrics side by side
Valuation
| Metric | APRE | GTBP |
|---|---|---|
| P/B ratio | 0.22 | 2.18 |
Profitability
| Metric | APRE | GTBP |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -31.99% | -618.74% |
| ROIC | -33.73% | -457.75% |
Growth (annualized)
| Metric | APRE | GTBP |
|---|---|---|
| Total return CAGR (5Y) | -63.30% | -73.13% |
Frequently asked
- How have APRE and GTBP total returns compared?
- Over the past 5 years, APRE delivered -63.30% and GTBP delivered -73.13% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.